1. Medicines with one seller and many buyers: strategies to increase the power of the payer;Rintoul;BMJ,2020
2. WHO. Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12: operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer. Geneva: World Health Organization, 2018. Available from: https://apps.who.int/iris/handle/10665/277190 (accessed 23 December 2020).
3. WHO/Europe. Better access to effective, novel and affordable medicines: a new vision for collaboration between the public and private sector. Regional Committee for Europe EUR/RC70/Inf.Doc./6, 70th session. Virtual session, 14–15 September 2020. Copenhagen: World Health Organization Regional Office for Europe, 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/334171/70id06e-AccessMed-200722.pdf?sequence=1&isAllowed=y (accessed 5 February 2021).
4. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13;Davis;BMJ,2017
5. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis;Vokinger;Lancet Oncol,2020